RPT-UPDATE 1-Novo Nordisk’s diabetes drug succeeds in key trial

Aug 16 (Reuters) – Novo Nordisk A/S said onWednesday its diabetes drug met the main goal of reducingglucose levels in patients in a key late-stage trial, settingthe stage for it to become the new standard therapy for type 2diabetes.
The post RPT-UPDATE 1-Novo Nordisk’s diabetes drug succeeds in key trial appeared first on RocketNews | Top News Stories From Around the Globe.